Table 1.

Patient’s clinical, immunological and therapeutic characteristics in the current series

Patient number	Age/sex	Time after COVID-19 vaccination	Type of vaccination	Clinical features	Immunological features	EULAR/ACR SLE classification criteria	Treatment	SLEDAI 2K (first visit)	SLEDAI 2K (last visit)
1	24/m	Seven days after the first dose	Pfizer BNT162b2 mRNA	Psoriasiform papulosquamous rash, a non-scarring alopecia, arthritis	Positive ANA 1/160, Ribosomal P, chromatin, and low C3	13	HCQ 200 mg BID, topical steroids, and etoricoxib	10	4
2	23/m	One month after the second dose	Pfizer BNT162b2 mRNA	Pancytopenia, fever, malar rash, oral ulcers, non-resolving headache, lymphadenopathy	Positive ANA 1/160, Ro/SSA, beta 2 glycoprotein IgG, direct Coombs	14	HCQ 200 mg BID, Prednisone 1 mg/kg, azathioprine 2 mg/kg, Granulocyte colony-stimulating factor and revolade	15	1
3	56/m	One month after second dose	Pfizer BNT162b2 mRNA	Arthritis, lymphadenopathy	Positive ANA 1/160, double-stranded DNA, smith, low c3	15	HCQ 200 mg BID and etoricoxib	8	4

COVID-19 coronavirus 19, ANA antinuclear antibodies, EULAR/ACR European League Against Rheumatism and the American College of Rheumatology, BID twice daily, DNA deoxyribonucleic acid, mRNA messenger ribonucleic acid, SLEDA 2K systemic lupus erythematosus disease activity index 2000, HCQ hydroxychloroquine